查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1298405

動脈粥樣硬化治療市場：按藥物類型、給藥途徑、分銷渠道劃分2023-2032年全球機會分析和行業預測

Atherosclerosis Drugs Market By Drug Type, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 250 Pages | 商品交期: 2-3個工作天內

價格

2022年動脈粥樣硬化治療市場價值為206.851億美元，預計到2032年將達到277.1192億美元，2023年至2032年復合年增長率為3%。

動脈粥樣硬化藥物市場-IMG1

動脈粥樣硬化是一種斑塊堆積導致靜脈狹窄和動脈壁硬化的疾病。斑塊在血管中積聚，阻礙血流並導致血壓升高。這種情況通常會導致血液中形成血栓，還可能導致心髒病、冠狀動脈疾病和外周動脈疾病。

動脈粥樣硬化藥物旨在通過降低膽固醇水平、抑制炎症、防止血栓和改善血流來減少斑塊形成及其對身體的影響。常用的動脈硬化藥物包括抗血小板藥物，如可防止血栓的阿司匹林、可降低血壓的血管緊張素轉換□（ACE）抑製劑，以及有助於維持血壓同時最大限度降低心髒病發作風險的BETA受體阻滯劑等。

全球動脈粥樣硬化治療市場的增長主要是由心血管疾病的驚人增加推動的。此外，人們對動脈粥樣硬化早期診斷和治療的認識不斷增強，推動了動脈粥樣硬化治療的需求，這對市場的增長產生了積極影響。然而，與動脈粥樣硬化治療研究和開發相關的成本激增預計將阻礙市場增長。相比之下，不僅公共部門而且私營部門對新藥治療的投資激增，預計這將為預測期內動脈粥樣硬化治療市場的增長提供利潤豐厚的機會。

此外，發達國家和發展中國家醫療保健支出的增加推動了對動脈粥樣硬化藥物的需求，因為醫療保健提供者尋求為患者提供最新、最有效的治療方法。

全球動脈粥樣硬化治療市場按藥物類型、給藥途徑、分銷渠道和地區細分。按藥物類型分為抗血小板/抗凝藥、降膽固醇藥、ACE抑製劑等。有兩種給藥途徑：口服和注射。按分銷渠道分為醫院藥房、在線供應商和藥店/零售藥房。

目錄

第 1 章 簡介

第二章執行摘要

第三章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資口袋
  • 波特五力分析
    • 供應商的議價能力
    • 買方議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭強度
  • 市場動態
    • 促進者
      • 全國肥胖率激增
      • 政府加大力度促進健康生活方式
      • 開發動脈硬化新療法
    • 阻礙因素
      • 動脈硬化藥物的副作用
    • 機會
      • 新興市場的增長機會
  • COVID-19 市場影響分析

4 動脈粥樣硬化治療市場（按藥物類型）

  • 概述
    • 市場規模和預測
  • 抗血小板和抗凝藥物
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家分類
  • 降膽固醇藥物
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • ACE抑製劑
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家

5 動脈粥樣硬化治療市場（按給藥途徑）

  • 概述
    • 市場規模和預測
  • 口服
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 注射
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家

6.動脈粥樣硬化治療市場（按分銷渠道）

  • 概述
    • 市場規模及預測
  • 醫院藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 在線提供商
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 藥店和零售藥店
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類

7.按地區劃分的動脈粥樣硬化治療市場

  • 概述
    • 市場規模/預測：按地區
  • 北美
    • 主要趨勢和機遇
    • 市場規模和預測：按藥物類型
    • 市場規模和預測：按管理途徑
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 加拿大
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
  • 歐洲
    • 主要趨勢和機遇
    • 市場規模和預測：按藥物類型
    • 市場規模和預測：按管理途徑
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 歐洲其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
  • 亞太地區
    • 主要趨勢和機遇
    • 市場規模和預測：按藥物類型
    • 市場規模和預測：按管理途徑
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 澳大利亞
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 韓國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 亞太其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機遇
    • 市場規模和預測：按藥物類型
    • 市場規模和預測：按管理途徑
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 巴西
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 沙特阿拉伯
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 南非
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10大公司產品圖
  • 比賽儀表板
  • 比賽熱圖
  • 2022 年頂級公司定位

第九章公司簡介

  • Amgen Inc.
  • Pfizer Inc.
  • AstraZeneca
  • Bayer AG
  • Sanofi
  • Novartis AG
  • Viatris Inc.
  • Bausch Health Companies Inc.
  • Lupin
  • Johnson & Johnson
Product Code: A13185

The atherosclerosis drugs market valued for $20,608.51 million in 2022 and is estimated to reach $27,711.92 million by 2032, exhibiting a CAGR of 3% from 2023 to 2032.

Atherosclerosis Drugs Market - IMG1

Atherosclerosis is a disorder in which veins get narrowed due to build of plaque, thus stiffening the artery walls. Blood flow is obstructed by plaque that builds up in blood vessels, which raises blood pressure. Formation of blood clots in the bloodstream is common in this condition, which can further lead to heart attack, coronary artery diseases, or peripheral artery diseases.

Atherosclerosis drugs aim to reduce the formation of plaque or its effects on the body by reducing cholesterol levels, decreasing inflammation, preventing blood clots, and improving blood flow. Commonly used atherosclerosis drugs include antiplatelet drugs such as aspirin, which prevent blood clots; angiotensin-converting enzyme (ACE) inhibitors, which reduce blood pressure; and beta-blockers, which minimize the risk of heart attack along with maintaining the blood pressure.

The growth of the global atherosclerosis drugs market is majorly driven by alarming increase in cardiovascular disorders. In addition, rise in awareness of early diagnosis and treatment of atherosclerosis boosts the demand for atherosclerosis drugs, which positively impacts the growth of the market. However, surge in cost associated with R&D of atherosclerosis drugs is expected to impede the market growth. In contrast, surge in investments for novel drug therapeutics in public as well as private sectors is anticipated to provide lucrative opportunities for the growth of the atherosclerosis drugs market during the forecast period.

Furthermore, rise in healthcare expenditure in both developed and developing countries drives demand for atherosclerosis drugs, as healthcare providers seek to offer the latest and most effective treatments to their patients.

The global atherosclerosis drugs market is segmented into drug type, route of administration, distribution channel, and region. On the basis of drug type, the market is categorized into anti-platelet & anticoagulants, cholesterol lowering medication, ACE inhibitors, and others. Depending on route of administration, it is bifurcated into oral and injectable. By distribution channel, it is classified into hospital pharmacies, online providers, and drug stores & retail pharmacies.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The report provides a comprehensive analysis of the key players that operate in the global atherosclerosis drugs market. The key companies profiled in the report include Amgen Inc., Pfizer Inc., AstraZeneca, Bayer AG, Sanofi, Novartis AG, Viatris, Johnson & Johnson, Lupin, and Bausch Health Companies Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the atherosclerosis drugs market analysis from 2022 to 2032 to identify the prevailing atherosclerosis drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the atherosclerosis drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global atherosclerosis drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type

  • Anti-platelet and Anticoagulants
  • Cholesterol Lowering Medication
  • ACE Inhibitors
  • Others

By Route of Administration

  • Oral
  • Injectable

By Distribution Channel

  • Hospital Pharmacies
  • Online Providers
  • Drug Stores and Retail Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Amgen Inc.
    • AstraZeneca
    • Bausch Health Companies Inc.
    • Bayer AG
    • Johnson & Johnson
    • Lupin
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Viatris Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Surge in obesity in populace
      • 3.4.1.2. Increase in government initiatives to promote healthy lifestyle
      • 3.4.1.3. Development of new treatments for atherosclerosis
    • 3.4.2. Restraints
      • 3.4.2.1. Side effects of atherosclerosis drugs
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunities in the emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Anti-platelet and Anticoagulants
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Cholesterol Lowering Medication
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. ACE Inhibitors
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Oral
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Injectable
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Online Providers
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Drug Stores and Retail Pharmacies
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: ATHEROSCLEROSIS DRUGS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Drug Type
    • 7.2.3. Market size and forecast, by Route of Administration
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Drug Type
      • 7.2.5.1.3. Market size and forecast, by Route of Administration
      • 7.2.5.1.4. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Drug Type
      • 7.2.5.2.3. Market size and forecast, by Route of Administration
      • 7.2.5.2.4. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Drug Type
      • 7.2.5.3.3. Market size and forecast, by Route of Administration
      • 7.2.5.3.4. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Drug Type
    • 7.3.3. Market size and forecast, by Route of Administration
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Drug Type
      • 7.3.5.1.3. Market size and forecast, by Route of Administration
      • 7.3.5.1.4. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Drug Type
      • 7.3.5.2.3. Market size and forecast, by Route of Administration
      • 7.3.5.2.4. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Drug Type
      • 7.3.5.3.3. Market size and forecast, by Route of Administration
      • 7.3.5.3.4. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Drug Type
      • 7.3.5.4.3. Market size and forecast, by Route of Administration
      • 7.3.5.4.4. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Drug Type
      • 7.3.5.5.3. Market size and forecast, by Route of Administration
      • 7.3.5.5.4. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Drug Type
      • 7.3.5.6.3. Market size and forecast, by Route of Administration
      • 7.3.5.6.4. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Drug Type
    • 7.4.3. Market size and forecast, by Route of Administration
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Drug Type
      • 7.4.5.1.3. Market size and forecast, by Route of Administration
      • 7.4.5.1.4. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Drug Type
      • 7.4.5.2.3. Market size and forecast, by Route of Administration
      • 7.4.5.2.4. Market size and forecast, by Distribution Channel
      • 7.4.5.3. Australia
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Drug Type
      • 7.4.5.3.3. Market size and forecast, by Route of Administration
      • 7.4.5.3.4. Market size and forecast, by Distribution Channel
      • 7.4.5.4. India
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Drug Type
      • 7.4.5.4.3. Market size and forecast, by Route of Administration
      • 7.4.5.4.4. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Drug Type
      • 7.4.5.5.3. Market size and forecast, by Route of Administration
      • 7.4.5.5.4. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Drug Type
      • 7.4.5.6.3. Market size and forecast, by Route of Administration
      • 7.4.5.6.4. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Drug Type
    • 7.5.3. Market size and forecast, by Route of Administration
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Drug Type
      • 7.5.5.1.3. Market size and forecast, by Route of Administration
      • 7.5.5.1.4. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Drug Type
      • 7.5.5.2.3. Market size and forecast, by Route of Administration
      • 7.5.5.2.4. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Drug Type
      • 7.5.5.3.3. Market size and forecast, by Route of Administration
      • 7.5.5.3.4. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Drug Type
      • 7.5.5.4.3. Market size and forecast, by Route of Administration
      • 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Amgen Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Pfizer Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. AstraZeneca
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Bayer AG
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Sanofi
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Novartis AG
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Viatris Inc.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Bausch Health Companies Inc.
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Lupin
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Johnson & Johnson
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 02. ATHEROSCLEROSIS DRUGS MARKET FOR ANTI-PLATELET AND ANTICOAGULANTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. ATHEROSCLEROSIS DRUGS MARKET FOR CHOLESTEROL LOWERING MEDICATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. ATHEROSCLEROSIS DRUGS MARKET FOR ACE INHIBITORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. ATHEROSCLEROSIS DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. GLOBAL ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 07. ATHEROSCLEROSIS DRUGS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. ATHEROSCLEROSIS DRUGS MARKET FOR INJECTABLE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 10. ATHEROSCLEROSIS DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. ATHEROSCLEROSIS DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. ATHEROSCLEROSIS DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. ATHEROSCLEROSIS DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 18. U.S. ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 19. U.S. ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 20. U.S. ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 21. CANADA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 22. CANADA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 23. CANADA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. UK ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 38. UK ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 39. UK ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 40. ITALY ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 41. ITALY ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 42. ITALY ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 55. JAPAN ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 56. CHINA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 57. CHINA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 58. CHINA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 59. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 60. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 61. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. INDIA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 63. INDIA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 64. INDIA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 71. LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 72. LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 74. LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 75. BRAZIL ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 78. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 79. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 80. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 81. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 82. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 83. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 84. REST OF LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 86. REST OF LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 87. AMGEN INC.: KEY EXECUTIVES
  • TABLE 88. AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 89. AMGEN INC.: PRODUCT SEGMENTS
  • TABLE 90. AMGEN INC.: PRODUCT PORTFOLIO
  • TABLE 91. AMGEN INC.: KEY STRATERGIES
  • TABLE 92. PFIZER INC.: KEY EXECUTIVES
  • TABLE 93. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 94. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 95. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 96. ASTRAZENECA: KEY EXECUTIVES
  • TABLE 97. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 98. ASTRAZENECA: PRODUCT SEGMENTS
  • TABLE 99. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 100. ASTRAZENECA: KEY STRATERGIES
  • TABLE 101. BAYER AG: KEY EXECUTIVES
  • TABLE 102. BAYER AG: COMPANY SNAPSHOT
  • TABLE 103. BAYER AG: PRODUCT SEGMENTS
  • TABLE 104. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 105. BAYER AG: KEY STRATERGIES
  • TABLE 106. SANOFI: KEY EXECUTIVES
  • TABLE 107. SANOFI: COMPANY SNAPSHOT
  • TABLE 108. SANOFI: PRODUCT SEGMENTS
  • TABLE 109. SANOFI: PRODUCT PORTFOLIO
  • TABLE 110. SANOFI: KEY STRATERGIES
  • TABLE 111. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 112. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 113. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 114. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 115. NOVARTIS AG: KEY STRATERGIES
  • TABLE 116. VIATRIS INC.: KEY EXECUTIVES
  • TABLE 117. VIATRIS INC.: COMPANY SNAPSHOT
  • TABLE 118. VIATRIS INC.: PRODUCT SEGMENTS
  • TABLE 119. VIATRIS INC.: PRODUCT PORTFOLIO
  • TABLE 120. BAUSCH HEALTH COMPANIES INC.: KEY EXECUTIVES
  • TABLE 121. BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
  • TABLE 122. BAUSCH HEALTH COMPANIES INC.: PRODUCT SEGMENTS
  • TABLE 123. BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
  • TABLE 124. LUPIN: KEY EXECUTIVES
  • TABLE 125. LUPIN: COMPANY SNAPSHOT
  • TABLE 126. LUPIN: PRODUCT SEGMENTS
  • TABLE 127. LUPIN: PRODUCT PORTFOLIO
  • TABLE 128. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 129. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 130. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 131. JOHNSON & JOHNSON: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. ATHEROSCLEROSIS DRUGS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF ATHEROSCLEROSIS DRUGS MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN ATHEROSCLEROSIS DRUGS MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALATHEROSCLEROSIS DRUGS MARKET
  • FIGURE 10. ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR ANTI-PLATELET AND ANTICOAGULANTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR CHOLESTEROL LOWERING MEDICATION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR ACE INHIBITORS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR INJECTABLE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. ATHEROSCLEROSIS DRUGS MARKET BY REGION, 2022
  • FIGURE 23. U.S. ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. CANADA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. MEXICO ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. GERMANY ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. FRANCE ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. UK ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. ITALY ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. SPAIN ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. REST OF EUROPE ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. JAPAN ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. CHINA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. INDIA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. REST OF ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. BRAZIL ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. REST OF LAMEA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46. COMPETITIVE DASHBOARD
  • FIGURE 47. COMPETITIVE HEATMAP: ATHEROSCLEROSIS DRUGS MARKET
  • FIGURE 48. TOP PLAYER POSITIONING, 2022
  • FIGURE 49. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 50. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 51. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 52. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 53. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 54. ASTRAZENECA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. ASTRAZENECA: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 56. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. SANOFI: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. SANOFI: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 61. SANOFI: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 62. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 63. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 64. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 65. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 66. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 67. BAUSCH HEALTH COMPANIES INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 68. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 69. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 70. LUPIN: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 71. LUPIN: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 72. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 73. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 74. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)